PortalPublikationenReducing the burden of bone metastases: current concepts and...

Reducing the burden of bone metastases: current concepts and treatment options

Standard

Reducing the burden of bone metastases: current concepts and treatment options. / von Moos, Roger; Sternberg, Cora; Body, Jean-Jacques; Bokemeyer, Carsten.

in: SUPPORT CARE CANCER, Jahrgang 21, Nr. 6, 01.06.2013, S. 1773-83.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

von Moos, R, Sternberg, C, Body, J-J & Bokemeyer, C 2013, 'Reducing the burden of bone metastases: current concepts and treatment options', SUPPORT CARE CANCER, Jg. 21, Nr. 6, S. 1773-83. https://doi.org/10.1007/s00520-013-1755-1

APA

von Moos, R., Sternberg, C., Body, J-J., & Bokemeyer, C. (2013). Reducing the burden of bone metastases: current concepts and treatment options. SUPPORT CARE CANCER, 21(6), 1773-83. https://doi.org/10.1007/s00520-013-1755-1

Vancouver

von Moos R, Sternberg C, Body J-J, Bokemeyer C. Reducing the burden of bone metastases: current concepts and treatment options. SUPPORT CARE CANCER. 2013 Jun 1;21(6):1773-83. https://doi.org/10.1007/s00520-013-1755-1

Bibtex

@article{ea93105da9e544fe9a56a774c0ece076,
title = "Reducing the burden of bone metastases: current concepts and treatment options",
abstract = "BACKGROUND: Bone metastases occur frequently in patients with solid tumours such as those of the prostate, breast and lung, and are associated with an increased risk of skeletal-related events (SREs). This article reviews the personal, social and economic burdens of bone metastases and SREs, and approaches to treatment.METHODS: PubMed searches were conducted using a broad range of search terms. Articles identified were refined by author review of abstracts. Additional material was identified by searching recent relevant congress abstracts.RESULTS: Bone metastases often decrease quality of life, but quantitative data on the extent of this effect are limited. Data from the USA demonstrate a significant financial burden associated with bone metastases; similar trends are now being uncovered in Europe as the number of assessments of health economics and healthcare resource utilisation in the region increases. The bisphosphonate zoledronic acid reduces the incidence of SREs compared with placebo. Recent phase 3 studies have shown that therapy with the RANK ligand inhibitor denosumab is superior to zoledronic acid for preventing or delaying SREs in patients with bone metastases from solid tumours. Denosumab also has a comparable safety profile to bisphosphonates, with reduced risk of renal toxicity and acute phase reactions. Data from Europe suggest that denosumab is cost-effective for the prevention of SREs compared with zoledronic acid. Additionally, several new experimental bone-targeted agents show promise.CONCLUSION: Recent progress may help to reshape evidence-based guidelines to improve patient care and reduce the economic burden of bone metastases.",
keywords = "Aged, Bone Density Conservation Agents, Bone Neoplasms, Breast Neoplasms, Cost of Illness, Cost-Benefit Analysis, Female, Humans, Lung Neoplasms, Male, Prostatic Neoplasms",
author = "{von Moos}, Roger and Cora Sternberg and Jean-Jacques Body and Carsten Bokemeyer",
year = "2013",
month = jun,
day = "1",
doi = "10.1007/s00520-013-1755-1",
language = "English",
volume = "21",
pages = "1773--83",
journal = "SUPPORT CARE CANCER",
issn = "0941-4355",
publisher = "Springer",
number = "6",

}

RIS

TY - JOUR

T1 - Reducing the burden of bone metastases: current concepts and treatment options

AU - von Moos, Roger

AU - Sternberg, Cora

AU - Body, Jean-Jacques

AU - Bokemeyer, Carsten

PY - 2013/6/1

Y1 - 2013/6/1

N2 - BACKGROUND: Bone metastases occur frequently in patients with solid tumours such as those of the prostate, breast and lung, and are associated with an increased risk of skeletal-related events (SREs). This article reviews the personal, social and economic burdens of bone metastases and SREs, and approaches to treatment.METHODS: PubMed searches were conducted using a broad range of search terms. Articles identified were refined by author review of abstracts. Additional material was identified by searching recent relevant congress abstracts.RESULTS: Bone metastases often decrease quality of life, but quantitative data on the extent of this effect are limited. Data from the USA demonstrate a significant financial burden associated with bone metastases; similar trends are now being uncovered in Europe as the number of assessments of health economics and healthcare resource utilisation in the region increases. The bisphosphonate zoledronic acid reduces the incidence of SREs compared with placebo. Recent phase 3 studies have shown that therapy with the RANK ligand inhibitor denosumab is superior to zoledronic acid for preventing or delaying SREs in patients with bone metastases from solid tumours. Denosumab also has a comparable safety profile to bisphosphonates, with reduced risk of renal toxicity and acute phase reactions. Data from Europe suggest that denosumab is cost-effective for the prevention of SREs compared with zoledronic acid. Additionally, several new experimental bone-targeted agents show promise.CONCLUSION: Recent progress may help to reshape evidence-based guidelines to improve patient care and reduce the economic burden of bone metastases.

AB - BACKGROUND: Bone metastases occur frequently in patients with solid tumours such as those of the prostate, breast and lung, and are associated with an increased risk of skeletal-related events (SREs). This article reviews the personal, social and economic burdens of bone metastases and SREs, and approaches to treatment.METHODS: PubMed searches were conducted using a broad range of search terms. Articles identified were refined by author review of abstracts. Additional material was identified by searching recent relevant congress abstracts.RESULTS: Bone metastases often decrease quality of life, but quantitative data on the extent of this effect are limited. Data from the USA demonstrate a significant financial burden associated with bone metastases; similar trends are now being uncovered in Europe as the number of assessments of health economics and healthcare resource utilisation in the region increases. The bisphosphonate zoledronic acid reduces the incidence of SREs compared with placebo. Recent phase 3 studies have shown that therapy with the RANK ligand inhibitor denosumab is superior to zoledronic acid for preventing or delaying SREs in patients with bone metastases from solid tumours. Denosumab also has a comparable safety profile to bisphosphonates, with reduced risk of renal toxicity and acute phase reactions. Data from Europe suggest that denosumab is cost-effective for the prevention of SREs compared with zoledronic acid. Additionally, several new experimental bone-targeted agents show promise.CONCLUSION: Recent progress may help to reshape evidence-based guidelines to improve patient care and reduce the economic burden of bone metastases.

KW - Aged

KW - Bone Density Conservation Agents

KW - Bone Neoplasms

KW - Breast Neoplasms

KW - Cost of Illness

KW - Cost-Benefit Analysis

KW - Female

KW - Humans

KW - Lung Neoplasms

KW - Male

KW - Prostatic Neoplasms

U2 - 10.1007/s00520-013-1755-1

DO - 10.1007/s00520-013-1755-1

M3 - SCORING: Journal article

C2 - 23468364

VL - 21

SP - 1773

EP - 1783

JO - SUPPORT CARE CANCER

JF - SUPPORT CARE CANCER

SN - 0941-4355

IS - 6

ER -